Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market

Home » Company Interviews » Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market

In this episode of CEOLIVE we’re joined by Mr. Thomas Equels, CEO of Hemispherx Biopharma, which trades on the NYSE under ticker HEB.

Hemispherx is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

The new management team has achieved several recent milestones including:

1. The first shipment of Ampligen delivered for sale in Europe utilizing the Early Access Program (EAP)

2. EAP in Europe extended to pancreatic cancer patients beginning in the Netherlands

3. FDA approval to increase price for US-based Ampligen cost recovery program

4. Initiated a commercial scale production plan with our primary contract manufacturer to meet anticipated future demands in both international programs as well as domestic programs

5. Collaboration with Millions Missing Canada to bring medication to Canadians for ME/CFS

6. Completed an intranasal human safety study of Ampligen plus FluMist® and has commenced full data analysis

7. Top-line results show intranasal Ampligen was generally well-tolerated

8. Continuing discussions with FDA to identify path toward approval for ME/CFS

9. Cut Burn rate by over 50% and still reached milestones

About Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials.

The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection.

The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

Forward Looking Statements

This LIVETRADES.TV video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.

Contact LIVETRADES.TV

Mike Elliott
me@livetrades.tv

Disclaimer

Neither LIVETRADES.TV or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video.

LIVETRADES content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in LIVETRADES content and productions, or other investor relations materials and presentations are subject to change. Neither LIVETRADES nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information is provided for informational or entertainment purposes only. LIVETRADES is not a registered broker-dealer or a registered investment advisor.

Sign Up Now for the Latest Trader Insights!
Signup today and receive top trading strategies. We will never share or sell your email address.
Author: Mike Elliott

Login

Lost your password?